News >

Expert Excited for Next Steps With CAR-T in Non-Hodgkin Lymphoma

Brandon Scalea
Published: Monday, Jun 10, 2019

Ahmed Galal, MD

Ahmed Galal, MD

The FDA approval of 2 CAR T-cell therapies to treat select patients with aggressive non-Hodgkin lymphoma (NHL) subtypes has filled a significant unmet need in the third-line setting. Still, certain obstacles are preventing this treatment from becoming more universally utilized, said Ahmed Galal, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x